Winners vs. losers in a bruised November: can the S&P 500 recover in December?

The S&P 500 fell about 0.6% in November, on track for its weakest November since 2021, as lithium and healthcare winners (Albemarle ~+30%, Eli Lilly +26.5% reaching $1tn market cap, Solventum +24%, Merck +22.4%, Expeditors +21% with EPS $1.64) were offset by steep declines in AI- and growth-linked names (Super Micro -36%, Axon -27%, Oracle -24% amid >$100bn debt, DoorDash -23%, The Trade Desk -22%). Market caution reflects uncertainty over AI monetization, elevated capex and financing risks, and valuation pressure heading into a historically strong December; strategists remain divided but major banks project substantial upside into 2026 (Deutsche Bank 8,000; HSBC/JPMorgan 7,500; Morgan Stanley ~7,800).

Analysis

Market structure: November bifurcated winners (lithium miners ALB, healthcare SOLV/MRK, logistics EXPD) and losers (AI infra/high-growth SMCI, ORCL, TTD, DASH) as investors rotated from duration/AI beta into defensives and commodity exposures. Supply shocks (CATL-linked mine outage) tightened lithium supply and lifted prices, giving miners near-term pricing power; conversely, heavy AI capex plans increase leverage for cloud/data center builders and compress margins for delivery/consumer names. Cross-asset: rising capex and debt concerns should widen IG credit spreads by 10–25bp if sentiment deteriorates, lift commodity ETFs (lithium) and depress growth-equity vols while raising put skew on AI names.

Risk assessment: Tail risks include AI monetization failure (low probability but >30% equity draw for AI-exposed names), Chinese EV demand slump reducing lithium prices >40%, and regulatory clampdowns on GLP-1/herbal drug pricing; each could materialize within 3–12 months. Immediate risk (days): earnings/guidance shocks (SMCI/ORCL). Short-term (weeks–months): capex announcements and debt refinancings; long-term (quarters–years): structural adoption of AI and EV penetration driving earnings.

Trade implications: Direct plays: overweight ALB (commodity supply tightness) and SOLV/MRK (defensive growth); underweight/short SMCI, ORCL, TTD, DASH where margins and financing are stretched. Use pair trades (long SOLV vs short TTD) to capture healthcare defensiveness vs ad cyclicality. Options: buy 3–9 month put spreads on ORCL/SMCI to limit cost and buy 6–9 month call spreads on ALB for asymmetric upside.

Contrarian angles: Consensus fears about AI monetisation may be partially priced; a selective dip in Q1 2026 could present entries into best-in-class AI infra providers with strong balance sheets, but ORCL’s >$100bn debt makes it a capital-structure risk not a pure technology play. Lithium’s rerating may be overdone if EV demand stalls—require 3 consecutive monthly lithium-price prints above current levels to justify doubling exposure. Watch credit spreads and Medicare GLP-1 policy as short-term catalysts that could flip the rotation.

Key Decisions for Investors

• Establish a 2–3% long position in ALB (Albemarle) via stock or a 6–9 month 10% ITM call spread (buy 1, sell 1 higher strike) targeting +25% upside in 6–9 months; set stop-loss at -18% from entry or trim on a +30% move.
• Initiate a 1–2% short exposure to SMCI via buying 3-month 5% OTM put spreads (limit capital at ~0.5% NAV risk) or small outright short (1–2% notional); catalyst: governance/earnings execution risk — cover if SMCI posts two consecutive quarters of margin recovery or issues buybacks.
• Execute a pair trade: long 2% SOLV (healthcare spin-off) vs short 2% TTD (The Trade Desk) to capture defensive/GLP-1 momentum vs ad-spend cyclical risk over 3–6 months; rebalance if SOLV outperforms by >25% or TTD gaps >20%.
• Buy a protective 6-month put spread on ORCL (e.g., buy 1 10% OTM put, sell 1 20% OTM put) sizing to hedge 1–2% of portfolio vs debt-driven downside; if ORCL credit spreads widen >50bp, increase hedge to 3% of NAV.
• Conditional action: monitor US Medicare GLP-1 reimbursement rules over next 30–60 days—if CMS expands coverage beyond initial framework, add +1–2% to healthcare winners (SOLV/MRK) within 10 trading days; if policy is restrictive, trim healthcare exposure by -1–2%.